Literature DB >> 11759067

Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

V Bronte1, P Serafini, E Apolloni, P Zanovello.   

Abstract

In the late 1970s, several findings suggested that accessory cells distinct from lymphocytes might suppress immune reactivity in tumor-bearing hosts. Studies in animal models and patients later confirmed that cells driven to act as dominant immune suppressors by growing cancers could subvert the immune system. These cells have also been termed natural suppressors, a functional definition connoting their ability to hamper various T- and B-lymphocyte responses without prior activation and independently from antigen and MHC restriction. These properties were attributed to distinct cell populations. The phenotypic discrepancies, together with the lack of antigen specificity, have generated serious restraints to research on tumor-induced suppression. Recent evidence indicates that suppressor cells are closely related to immature myeloid precursors and can be found in several situations that can exert adverse effects on the immunotherapy of cancer. The present review is an attempt to address the nature and properties of immature myeloid suppressors and their relationship to dendritic cells and macrophages, with the aim of clarifying the complex network of tumor-induced, negative regulators of the immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11759067     DOI: 10.1097/00002371-200111000-00001

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  81 in total

1.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.

Authors:  Baisakhi Raychaudhuri; Patricia Rayman; Joanna Ireland; Jennifer Ko; Brian Rini; Ernest C Borden; Jorge Garcia; Michael A Vogelbaum; James Finke
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 3.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

4.  Conditions that diminish myeloid-derived suppressor cell activities stimulate cross-protective immunity.

Authors:  Douglas M Heithoff; Elena Y Enioutina; Diana Bareyan; Raymond A Daynes; Michael J Mahan
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

Review 5.  Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.

Authors:  Thorsten Hagemann; Subhra K Biswas; Toby Lawrence; Antonio Sica; Claire E Lewis
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

6.  NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.

Authors:  Adam W Mailloux; M Rita I Young
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  Retinoic acid in the immune system.

Authors:  Karina Pino-Lagos; Micah J Benson; Randolph J Noelle
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci.

Authors:  Sally A DuPré; Doug Redelman; Kenneth W Hunter
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

Review 9.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

10.  Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

Authors:  S Peter Bak; Anselmo Alonso; Mary Jo Turk; Brent Berwin
Journal:  Mol Immunol       Date:  2008-09-27       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.